XML 28 R19.htm IDEA: XBRL DOCUMENT

Disaggregation of Revenues and Concentration Risk

3 Months Ended

Mar. 31, 2021

Disaggregation of Revenues and Concentration Risk

13. Disaggregation of Revenues and Concentration Risk

The following table presents the percentage of consolidated revenues generated by unaffiliated customers that individually represent greater than ten percent of consolidated revenues:

	Three Months Ended March 31,
	2021		2020
Medicare for DetermaRx™		27%		-%
Medicare Advantage for DetermaRx™		27%		-
Pharma Services Company A		20%		*
Pharma Services Company B		15%		*

*	Less than 10%

The following table presents the percentage of consolidated revenues attributable to products or services classes that represent greater than ten percent of consolidated revenues:

	Three Months Ended March 31,
	2021		2020
DetermaRx™		54%		10%
Pharma Services		46%		90%
Total		100%		100%

The following table presents the percentage of consolidated revenues attributable to geographical locations:

	Three Months Ended March 31,
	2021		2020
United States		57%		95%
Outside of the United States – Pharma Services		43%		5%
Total		100%		100%

The following table presents accounts receivable, as a percentage of total consolidated accounts receivables, from third-party payers and other customers that provided in excess of 10% of Oncocyte’s total accounts receivable.

	March 31, 2021		December 31, 2020
Pharma Services Company A		24%		35%
Medicare for DetermaRx™		16%		45%
Pharma Services Company B		18%		-
Medicare Advantage for DetermaRx™		38%		-